Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in Asthma and COPD patients

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 4, 2014, Pages 279-289

  Daley Yates, Peter T ^a   Mehta, Rashmi ^b   Chan, Robert H ^a   Despa, Simona X ^b   Louey, Margaret D ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

asthma; chronic obstructive pulmonary disease; dry powder inhaler; fluticasone propionate; pharmacokinetics; salmeterol

Indexed keywords

FLUTICASONE PROPIONATE; HYDROCORTISONE; SALMETEROL; AEROSOL; ANDROSTANE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; POWDER; SALBUTAMOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; AEROSOL; ANALOGS AND DERIVATIVES; AUSTRALIA; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; NEW ZEALAND; PATHOPHYSIOLOGY; POWDER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AEROSOLS; AGED; ALBUTEROL; ANDROSTADIENES; AREA UNDER CURVE; ASTHMA; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEW SOUTH WALES; NEW ZEALAND; PARTICLE SIZE; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905491626     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1040     Document Type: Article

References (13)

1. GINA: Global strategy for asthma management and prevention. NHLBI/WHO/GARD, Washington, DC; 2006 - updated 2011. Available at: http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html. Accessed November 2012.
2. GOLD: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006) - updated 2011. Available at: http://www.goldcopd .org/guidelines-global-strategy-for-diagnosis-management .html. Accessed November 2012.
3. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, and Ortega HG: Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 lg and fluticasone propionate 250 lg: implications for establishing bioequivalence of inhaled products. Clin Ther. 2009;31:370-385.
4. GlaxoSmithKline study SAS10006: A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the DISKUS (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the DISKUS. Available at: http://ctr.gsk.co.uk/welcome.asp. Accessed November 2012.
5. Clearie KL, Williamson PA, Vaidyanathan S, Du Bois J, Nell H, and Lipworth BJ: Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br J Clin Pharmacol. 2010;69:637-644.
6. Daley-Yates PT: The clinical utility of pharmacokinetics in demonstrating bioequivalence of locally acting orally inhaled drugs. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young, (eds). Respiratory Drug Delivery 2010, Vol. 1. Davis Healthcare International Publishing, River Grove, IL: pp. 273-283, 2010.
7. Daley-Yates PT, and Parkins DA: Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv. 2011;8:1297-1308.
8. O'Connor D, Adams WP, Chen ML, Daley-Yates P, Davis J, Derendorf H, Ducharme MP, Fuglsang A, Herrle M, Hochhaus G, Holmes SM, Lee SL, Li BV, Lyapustina S, Newman S, Oliver M, Patterson B, Peart J, Poochikian G, Roy P, Shah T, Singh GJ, and Sharp SS: Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv. 2011;24:119-135.
9. Byron PR: Quality by design (QbD): what type of in vivoin vitro correlations are feasible? In: RN Dalby, PR Byron, J Peart, JD Suman, S Farr, and PM Young, (eds). Respiratory Drug Delivery 2008, Vol. 1. Davis Healthcare International Publishing, River Grove, IL: pp. 125-132, 2008.
10. Newman SP: How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med. 1998;11(Suppl. 1):S97-S104.
11. Newhouse MT, Dobranowski JA, Chambers C, Dobranowski J, and Dobranowski M: Development and preliminary validation studies with an ex vivo oropharyngeal model. In: PR Byron, RN Dalby, and SJ Farr, (eds). Proceedings of Respiratory Drug Delivery VI. Interpharm Press Inc., Buffalo Grove, IL; pp. 389-391, 1998.
12. Cheng Y-S, Zhou Y, and Chen BT: Particle deposition in a cast of human oral airways. Aerosol Sci Technol. 1999;31:286-300.
13. Burnell PKP, Malton A, Reavill K, and Ball MHE: Design, validation and initial testing of the electronic lung device. J. Aerosol Sci. 1998;29:1011-1025.